Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide versus lactulose for constipation-predominant irritable bowel syndrome
ChiCTR2100050993Phase 4Recruiting
- Sponsor
- People's Hospital of Tongliang District, Chongqing
- Start
- Jan 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of linaclotide and lactulose in irritable bowel syndrome (IBS) (2 arms), sponsored by People's Hospital of Tongliang District, Chongqing. Primary endpoints: Abdominal pain score and Number of complete spontaneous bowel movements per week. Started Jan 2021; status: recruiting.
02
Drugs
linaclotidelactulose
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on ChiCTR2100050993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050993.